Published in Blood on January 22, 2013
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood (2014) 2.07
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res (2015) 1.81
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica (2015) 1.10
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood (2015) 1.01
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle (2013) 0.98
The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica (2013) 0.98
Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood (2015) 0.97
Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther (2013) 0.96
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget (2014) 0.96
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk (2014) 0.88
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica (2014) 0.87
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin (2015) 0.84
Do mantle cell lymphomas have an 'Achilles heel'? Curr Opin Hematol (2014) 0.82
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomark Res (2013) 0.81
Idelalisib in the management of lymphoma. Blood (2016) 0.80
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov (2016) 0.79
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia. Leuk Res Rep (2015) 0.78
PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. J Exp Clin Cancer Res (2016) 0.77
Identifying molecular features associated with psychoneurological symptoms in women with breast cancer using multivariate mixed models. Cancer Inform (2015) 0.77
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol (2016) 0.76
B-cell receptor pathway modulators in NHL. Hematology Am Soc Hematol Educ Program (2015) 0.76
Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia (2015) 0.75
PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro. Onco Targets Ther (2017) 0.75
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth. Cancer Biol Med (2015) 0.75
Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene (2016) 0.75
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med (2005) 3.96
PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol (2003) 3.92
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87
Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci (2005) 3.45
PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol (2012) 3.11
P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A (1997) 3.09
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood (2010) 2.33
The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal (2010) 2.15
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res (2010) 2.00
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A (2007) 1.98
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood (2006) 1.58
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol (2005) 1.54
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res (2010) 1.49
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood (2008) 1.43
The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia (2011) 1.43
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci (2008) 1.39
Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol (2005) 1.37
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene (2009) 1.35
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res (2009) 1.12
Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett (2005) 1.05
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch (2010) 1.01
GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle (2008) 0.97
Gene targeting: attention to detail. Cell (2004) 0.95
Progress in mantle-cell lymphoma. J Clin Oncol (2008) 0.92
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol (2007) 2.36
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol (2007) 2.35
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood (2004) 2.30
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. J Inorg Biochem (2007) 1.84
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol (2006) 1.68
Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression. Haematologica (2008) 1.64
Cardiac surgery in octogenarians: long-term survival, functional status, living arrangements, and leisure activities. Ann Thorac Surg (2010) 1.64
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 1.63
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol (2007) 1.62
The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood (2013) 1.62
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood (2011) 1.57
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood (2011) 1.51
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol (2006) 1.45
High rate of neoplastic cells with genetic abnormalities in proliferation centers of chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.45
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res (2005) 1.44
Allogeneic Transplantation for Chronic Lymphocytic Leukemia in the Age of Novel Treatment Strategies. Oncology (Williston Park) (2016) 1.38
Renal failure after cardiac surgery: timing of cardiac catheterization and other perioperative risk factors. Ann Thorac Surg (2007) 1.35
Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica (2012) 1.31
AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res (2009) 1.30
Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol (2007) 1.28
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol (2009) 1.24
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood (2009) 1.21
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci Signal (2013) 1.20
HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell (2013) 1.18
EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood (2013) 1.17
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 1.15
Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration. Am J Pathol (2007) 1.15
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk (2010) 1.15
Vascular access-related infections: definitions, incidence rates, and risk factors. Am J Kidney Dis (2008) 1.12
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res (2013) 1.12
Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood (2010) 1.12
EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest (2012) 1.12
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res (2007) 1.09
Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol (2012) 1.09
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer (2006) 1.08
Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res (2008) 1.05
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood (2013) 1.02
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One (2013) 1.02
Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood (2014) 1.01
Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood (2004) 1.01
ROR1 expression is not a unique marker of CLL. Hematol Oncol (2011) 1.01
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 1.00
Association of dialysis modality with risk for infection-related hospitalization: a propensity score-matched cohort analysis. Clin J Am Soc Nephrol (2012) 1.00
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood (2010) 0.95
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res (2003) 0.94
Impact of a specialized multidisciplinary tracheostomy team on tracheostomy care in critically ill patients. Can J Surg (2011) 0.93
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol (2007) 0.92
Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review. Cancer Imaging (2013) 0.92
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol (2009) 0.90
Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood (2011) 0.89
Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagn Pathol (2012) 0.88
Structural analysis of oval-cell-mediated liver regeneration in rats. Hepatology (2012) 0.87
Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol (2008) 0.87
Vascular access-related bloodstream infections in First Nations, community and teaching Canadian dialysis units, and other centre-level predictors. Nephron Clin Pract (2009) 0.85
Multicentric reticulohistiocytosis and urologic carcinomas: a possible paraneoplastic association. J Cutan Pathol (2010) 0.85
Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol (2009) 0.85
Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol (2013) 0.85
Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med (2003) 0.85
Eruptive xanthomas as a cutaneous manifestation of hypertriglyceridemia: a case report. J Clin Aesthet Dermatol (2011) 0.84
GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol (2013) 0.84
Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica (2010) 0.84
Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol (2013) 0.84
Plasma morphine and metabolite concentrations are associated with clinical effects of morphine in cancer patients. J Pain Symptom Manage (2012) 0.84
Refining the treatment of follicular lymphoma. Leuk Lymphoma (2008) 0.84